WANY
GANX icon

Wealthspire Advisors (New York)’s Gain Therapeutics GANX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8K Hold
16,900
– – ﹤0.01% 914
2025
Q4 		$54.4K Buy
+16,900
New +$45.1K ﹤0.01% 1023

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Wealthspire Advisors (New York)'s GANX Position: Q1 2026 in Review

Wealthspire Advisors (New York) held its Gain Therapeutics (GANX) position steady in Q1 2026 at 16,900 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #914.

Wealthspire Advisors (New York) first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $54.4K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Wealthspire Advisors (New York) held 16,900 shares of Gain Therapeutics worth $32.8K as of Q1 2026.
  • Wealthspire Advisors (New York) left its Gain Therapeutics share count unchanged in Q1 2026.
  • Gain Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #914 holding.
  • Wealthspire Advisors (New York) first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Wealthspire Advisors (New York)'s Gain Therapeutics position peaked at $54.4K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.